Twin Peaks Wealth Advisors, LLC Halozyme Therapeutics, Inc. Transaction History
Twin Peaks Wealth Advisors, LLC
- $309 Billion
- Q2 2025
A detailed history of Twin Peaks Wealth Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Twin Peaks Wealth Advisors, LLC holds 53 shares of HALO stock, worth $3,455. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53Holding current value
$3,455% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
606Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$798 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$387 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$226 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$222 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.08B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...